Sitrin Capital Management’s Charles River Laboratories CRL Stock Holding History

Sitrin Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-19,255	Closed	-$5.47M	–	38
2022 Q1	$5.47M	Buy	19,255 +8	+0%	+$2.47K	2.74%	25
2021 Q4	$7.25M	Buy	19,247 +28	+0.1%	+$10.9K	3.41%	15
2021 Q3	$7.93M	Sell	19,219 -40	-0.2%	-$16.6K	3.8%	6
2021 Q2	$7.12M	Sell	19,259 -7,674	-28%	-$2.56M	3.21%	15
2021 Q1	$7.81M	Sell	26,933 -113	-0.4%	-$31.4K	3.7%	2
2020 Q4	$6.76M	Buy	27,046 +264	+1%	+$62.9K	3.37%	6
2020 Q3	$6.13M	Buy	+26,782	New	+$5.56M	3.25%	14

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sitrin Capital Management's CRL Position: Q2 2022 in Review

Sitrin Capital Management sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 19,255 shares — an estimated $5.47M sold.

Sitrin Capital Management first reported a position in CRL in Q3 2020 and held it in 7 quarters. The position peaked at $7.93M in Q3 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

Sitrin Capital Management reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
Sitrin Capital Management sold 19,255 Charles River Laboratories shares in Q2 2022, an estimated $5.47M.
Sitrin Capital Management first reported a position in Charles River Laboratories in Q3 2020 and held it in 7 quarters.
Sitrin Capital Management's Charles River Laboratories position peaked at $7.93M in Q3 2021.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Sitrin Capital Management's 13F filing for Q2 2022, filed 22 Jul 2022.